annb0t
Top 20
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ --Â Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise stated.[1] All figures are provided on an unaudited basis. (PRNewsfoto/Telix Pharmaceuticals Limited)
Financial Summary
Telix reports total revenue of $55.3 million from global sales of Illuccix, ...
>>> Read more: Telix Reports Third Quarter 2022 Financial Results
Financial Summary
Telix reports total revenue of $55.3 million from global sales of Illuccix, ...
>>> Read more: Telix Reports Third Quarter 2022 Financial Results
